Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Advances in allograft monitoring after intestinal transplantation

Lauro, Augusto; Marino, Ignazio R.; Matsumoto, Cal S.

Current Opinion in Organ Transplantation: April 2016 - Volume 21 - Issue 2 - p 165–170
doi: 10.1097/MOT.0000000000000279

Purpose of review The intestinal allograft, with an enormous lymphoid load, is a highly immunogenic organ which elicits a strong alloimmune response. In the early posttransplant period, a robust graft biopsy protocol via a temporary ileostomy is utilized for surveillance to detect rejection. In the later posttransplant period, after enteral continuity is reestablished, graft biopsies via a colonoscopy become more cumbersome. Alternative methods for intestinal allograft monitoring other than graft biopsy are of particular interest.

Recent findings Biomarkers and diagnostic tools, such as granzyme B, perforin, fecal calprotectin, citrulline, donor-specific antibody, and zoom video endoscopy have all been studied for application as reliable methods of performing intestinal allograft surveillance. Each modality has the capability to monitor a separate and unique process in the host-allograft immune response.

Summary The goal to find a reliable, reproducible, and noninvasive method for intestinal graft monitoring remains an elusive one. Many of the current modalities available only serve to act as complementary tests in conjunction with astute clinical observations. Graft biopsy remains the gold standard for monitoring the intestinal allograft.

aLiver and Multiorgan Transplant Unit, St. Orsola University Hospital, Bologna, Italy

bSidney Kimmel Medical College – Thomas Jefferson University, Philadelphia, Pennsylvania

cMedStar Georgetown Transplant Institute, Georgetown University Hospital, Washington, District of Columbia, USA

Correspondence to Augusto Lauro, MD, PhD, Attending Surgeon, Liver and Multiorgan Transplant Unit, St. Orsola University Hospital, Bologna, Italy. Tel: +39 340 071 6669, Mobile: +39 338 8663 879; e-mail:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.